Related Experiment Video
Updated: Mar 14, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Advances in Radiation Therapy for Primary Bone Malignancies
Luyuan Li1,2, Wensi Tao3, Josiane E Eid2
1Department of Medicine, North Alabama Medical Center, Florence, AL, USA.
Abstract:
Primary bone malignancies - including chordoma, chondrosarcoma, osteosarcoma, and Ewing sarcoma - originate from bone or cartilage cells and often develop in anatomically complex or surgically challenging regions. While surgical resection remains the standard of care for most localized tumors, radiation therapy (RT) has become an increasingly integral component of multidisciplinary management, particularly when complete surgical excision is not feasible, margins are close or positive, or the tumor is adjacent to critical structures. Historically, conventional photon-based RT has shown limited efficacy in many of these tumors due to factors such as relative radioresistance and proximity to radiosensitive normal tissues. However, advances in conformal photon techniques such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), along with hadron-based approaches like proton beam therapy (PBT) and carbon ion radiation therapy (CIRT), have expanded the therapeutic potential of RT in bone sarcomas. This review highlights the evolving role of RT in the management of primary bone malignancies, with a focus on technological advances, clinical outcomes, ongoing trials, and future directions in the field.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...

